1. Glucosylceramide synthase modulation ameliorates murine renal pathologies and promotes macrophage effector function in vitro
- Author
-
Agnes Cheong, Florin Craciun, Hervé Husson, Joseph Gans, Javier Escobedo, Yi-Chien Chang, Lilu Guo, Mariana Goncalves, Nathan Kaplan, Laurie A. Smith, Sarah Moreno, Joseph Boulanger, Shiguang Liu, Jacqueline Saleh, Mindy Zhang, Anna S. Blazier, Weiliang Qiu, Andrew Macklin, Tejaswi Iyyanki, Clément Chatelain, Shameer Khader, Thomas A. Natoli, Oxana Ibraghimov-Beskrovnaya, Dimitry Ofengeim, and Jonathan D. Proto
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Abstract While significant advances have been made in understanding renal pathophysiology, less is known about the role of glycosphingolipid (GSL) metabolism in driving organ dysfunction. Here, we used a small molecule inhibitor of glucosylceramide synthase to modulate GSL levels in three mouse models of distinct renal pathologies: Alport syndrome (Col4a3 KO), polycystic kidney disease (Nek8 jck ), and steroid-resistant nephrotic syndrome (Nphs2 cKO). At the tissue level, we identified a core immune-enriched transcriptional signature that was shared across models and enriched in human polycystic kidney disease. Single nuclei analysis identified robust transcriptional changes across multiple kidney cell types, including epithelial and immune lineages. To further explore the role of GSL modulation in macrophage biology, we performed in vitro studies with homeostatic and inflammatory bone marrow-derived macrophages. Cumulatively, this study provides a comprehensive overview of renal dysfunction and the effect of GSL modulation on kidney-derived cells in the setting of renal dysfunction.
- Published
- 2024
- Full Text
- View/download PDF